Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Generation and characterization of a human induced pluripotent stem (iPS) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the CALR 52bp deletion and the ASXL1 p.R693X mutation.
Gomez Limia CE, Devalle S, Reis M, Sochacki J, Carneiro M, Madeiro da Costa R, D'Andrea M, Padilha T, Zalcberg IR, Solza C, Daumas A, Rehen S, Monte-Mór B, Bonamino MH. Gomez Limia CE, et al. Among authors: daumas a. Stem Cell Res. 2017 Oct;24:16-20. doi: 10.1016/j.scr.2017.08.006. Epub 2017 Aug 8. Stem Cell Res. 2017. PMID: 29034885 Free article.
Characterization of a human induced Pluripotent Stem (iPS) cell line (INCABRi002-A) derived from a primary myelofibrosis patient harboring the 5-bp insertion in CALR and the p.W146X mutation in TP53.
Gomez Limia CE, Devalle S, Reis M, Sochacki J, Madeiro da Costa R, D'Andrea M, Padilha T, Zalcberg IR, Solza C, Daumas A, Rehen S, Bonamino MH, Monte-Mór B. Gomez Limia CE, et al. Among authors: daumas a. Stem Cell Res. 2018 Dec;33:130-134. doi: 10.1016/j.scr.2018.09.012. Epub 2018 Sep 20. Stem Cell Res. 2018. PMID: 30343103 Free article.
Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.
Monte-Mor Bda C, Ayres-Silva Jde P, Correia WD, Coelho AC, Solza C, Daumas AH, Bonamino MH, Santos FP, Datoguia TS, Pereira Wde O, Lisboa BC, Ramos CF, Machado-Neto JA, Hamerschlak N, Campregher PV, Traina F, Pagnano KB, Zalcberg I. Monte-Mor Bda C, et al. Blood Cells Mol Dis. 2016 Sep;60:74-7. doi: 10.1016/j.bcmd.2016.03.003. Epub 2016 Mar 8. Blood Cells Mol Dis. 2016. PMID: 26994960 Clinical Trial. No abstract available.
Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study.
Billet AC, Thibault T, Liozon É, De Boysson H, Perard L, Espitia O, Daumas A, De Pinho QG, Durel CA, Hot A, Bienvenu B, Humbert S, Bachmeyer C, Mainbourg S, Sené T, Devilliers H, Bailloud BD, Greigert H, Cochet A, Bonnotte B, Alberini JL, Samson M; French Study Group for Large Vessel Vasculitis (GEFA). Billet AC, et al. Among authors: daumas a. Eur J Intern Med. 2024 Apr 15:S0953-6205(24)00145-6. doi: 10.1016/j.ejim.2024.03.037. Online ahead of print. Eur J Intern Med. 2024. PMID: 38627183 Free article.
Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients.
Mottier D, Girard P, Couturaud F, Lacut K, Le Moigne E, Paleiron N, Guellec D, Sanchez O, Cogulet V, Laporte S, Marhic G, Mismetti P, Presles E, Robert-Ebadi H, Mahé I, Plaisance L, Reny JL, Darbellay Farhoumand P, Cuvelier C, Le Henaff C, Lambert Y, Danguy des Deserts M, Rousseau Legrand C, Boutreux S, Bleher Y, Decours R, Trinh-Duc A, Armengol G, Benhamou Y, Daumas A, Guyot SL, De Carvalho H, Lamia B, Righini M, Meyer G, Le Gal G. Mottier D, et al. Among authors: daumas a. NEJM Evid. 2023 Aug;2(8):EVIDoa2200332. doi: 10.1056/EVIDoa2200332. Epub 2023 Jun 27. NEJM Evid. 2023. PMID: 38320142 Clinical Trial.
124 results